Supreme Court backs Hikma in patent
Analysis based on 8 articles · First reported Jun 04, 2026 · Last updated Jun 04, 2026
The ruling by the United States — Supreme Court of the United States>>> is expected to benefit generic drugmakers like Hikma Pharmaceuticals>>> by reducing their vulnerability to patent lawsuits, potentially leading to more affordable generic drugs entering the market. Conversely, it represents a setback for brand-name pharmaceutical companies like Amarin Corporation>>>, which rely on patent protection for their products, potentially impacting their revenue from patented drugs.
The U.S. Supreme Court unanimously ruled that Hikma Pharmaceuticals>>>'s generic version of Amarin Corporation>>>'s cardiovascular drug Vascepa, sold with a 'skinny label,' did not infringe on Amarin Corporation>>>'s patents. This decision overturns a lower court's ruling and is seen as a significant win for generic drugmakers, potentially making them less susceptible to patent lawsuits when using 'skinny labels' that omit patented uses of a brand-name drug. The ruling was supported by President Donald Trump>>>'s administration and is expected to encourage generic competition, leading to lower drug prices. Amarin Corporation>>>, whose only product is Vascepa, expressed disappointment, while Hikma Pharmaceuticals>>> welcomed the decision, emphasizing its commitment to providing affordable medicines. Justice Ketanji Brown Jackson>>> authored the opinion, stating that Amarin Corporation>>> failed to show that Hikma Pharmaceuticals>>> actively encouraged infringing uses.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard